{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:19:11Z","timestamp":1788279551339,"version":"build-2803163510"},"reference-count":12,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>We hypothesized that a time\u2010limited frontline treatment strategy with abbreviated chemoimmunotherapy followed by targeted consolidation could achieve durable disease control with manageable toxicity in CLL. We evaluated the safety and efficacy of short\u2010course bendamustine\/rituximab (BR) induction followed by venetoclax\/rituximab (VR) consolidation. In a multicenter, single\u2010arm Phase 2 trial (NCT03609593), previously untreated CLL\/SLL needing therapy received BR for three 28\u2010day cycles followed by venetoclax ramp\u2010up to 400\u00a0mg daily plus rituximab every 28\u00a0days for six cycles; venetoclax continued to 12 cycles (total treatment, 15\u00a0months). The primary endpoint was overall response rate (ORR); key secondary endpoints included uMRD, PFS\/OS, and safety per CTCAE v4. Forty\u2010two patients were enrolled (median age 61.5\u00a0years; 64% unmutated IGHV; 29% complex karyotype; 10% TP53 aberrancy); 93% completed all planned therapy. At end of treatment, ITT ORR was 86% (CR\/CRi 64%, PR 21%); among efficacy\u2010evaluable patients, ORR was 100% (CR\/CRi 75%). End\u2010of\u2010therapy uMRD was achieved by 83% in bone marrow and 84% in blood among efficacy\u2010evaluable patients. Three\u2010year PFS and OS were 87.5% and 92.7%. TLS risk was downstaged after BR, and no TLS events occurred. Febrile neutropenia occurred in 12% of patients. Two on\u2010study deaths due to COVID\u201019 occurred; no Richter transformation occurred. Time\u2010limited BR\u2010VR achieved high uMRD rates and durable remissions with a manageable safety profile. While the treatment landscape in CLL has largely shifted toward chemotherapy\u2010free regimens, these data demonstrate the biological proof\u2010of\u2010concept that limited induction chemotherapy can effectively mitigate TLS risk and facilitate safe outpatient ramp\u2010up of venetoclax.<\/jats:p>","DOI":"10.1002\/hon.70205","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:54:41Z","timestamp":1780592081000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bendamustine\/Rituximab Induction Followed by Venetoclax\/Rituximab Consolidation in Frontline Treatment of Chronic Lymphocytic Leukemia: A Phase 2 Multi\u2010Center Study"],"prefix":"10.1002","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7653-4792","authenticated-orcid":false,"given":"Andrew H.","family":"Lipsky","sequence":"first","affiliation":[{"name":"Herbert Irving Comprehensive Cancer Center, Division of Hematology &amp; Oncology, Department of Medicine Columbia University Irving Medical Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8781-3327","authenticated-orcid":false,"given":"Brian T.","family":"Hill","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology Cleveland Clinic Taussig Cancer Center  Cleveland Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Winter","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology Cleveland Clinic Taussig Cancer Center  Cleveland Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer Henick","family":"Bachow","sequence":"additional","affiliation":[{"name":"Eugene M. &amp; Christine E. Lynn Cancer Institute Boca Raton Regional Hospital  Boca Raton Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Sender","sequence":"additional","affiliation":[{"name":"Herbert Irving Comprehensive Cancer Center, Division of Hematology &amp; Oncology, Department of Medicine Columbia University Irving Medical Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Weissbrot","sequence":"additional","affiliation":[{"name":"Herbert Irving Comprehensive Cancer Center, Division of Hematology &amp; Oncology, Department of Medicine Columbia University Irving Medical Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7039-0110","authenticated-orcid":false,"given":"Aaron D.","family":"Viny","sequence":"additional","affiliation":[{"name":"Herbert Irving Comprehensive Cancer Center, Division of Hematology &amp; Oncology, Department of Medicine Columbia University Irving Medical Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd L.","family":"Rosenblat","sequence":"additional","affiliation":[{"name":"Herbert Irving Comprehensive Cancer Center, Division of Hematology &amp; Oncology, Department of Medicine Columbia University Irving Medical Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark L.","family":"Heaney","sequence":"additional","affiliation":[{"name":"Herbert Irving Comprehensive Cancer Center, Division of Hematology &amp; Oncology, Department of Medicine Columbia University Irving Medical Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Jurcic","sequence":"additional","affiliation":[{"name":"Herbert Irving Comprehensive Cancer Center, Division of Hematology &amp; Oncology, Department of Medicine Columbia University Irving Medical Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Lamanna","sequence":"additional","affiliation":[{"name":"Herbert Irving Comprehensive Cancer Center, Division of Hematology &amp; Oncology, Department of Medicine Columbia University Irving Medical Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024631"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(24)00196\u20107"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000336"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011574"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v128.22.3243.3243"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010021\u201001280\u20108"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010023\u201000890\u2010y"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010018\u20100276\u20109"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.261107"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1713976"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022730"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2409804"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.70205","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hon.70205","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.70205","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:36:28Z","timestamp":1788276988000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.70205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1002\/hon.70205"],"URL":"https:\/\/doi.org\/10.1002\/hon.70205","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"2026-01-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70205"}}